|
1
|
Qin B, Chen Y, Yang K, Wang R, Yu L, Wang N, Liu S. An Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS) Method for Qualifying DAPB in Rat Plasma and Application to Pharmacokinetic Studies. Molecules 2024; 29:541. [PMID: 38276619 PMCID: PMC10818329 DOI: 10.3390/molecules29020541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Revised: 01/18/2024] [Accepted: 01/19/2024] [Indexed: 01/27/2024] Open
Abstract
DAPB, a new molecule including danshensu, borneol, and a mother nucleus of ACEI (Angiotensin-converting enzyme inhibitors), is being developed as an antihypertensive candidate compound. A rapid, accurate, and sensitive ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was established and validated for the determination of DAPB in rat plasma. Chromatographic separation was performed on an Agilent SB-C18 column after protein precipitation by acetonitrile with a mobile phase consisting of acetonitrile and deionized water with 0.02% formic acid and 5 mM NH4F (v/v) at a flow rate of 0.2 mL/min. Quantification was performed using electrospray positive ionization mass spectrometry in the multiple reaction monitoring (MRM) mode. The method was linear over the range of 2-1000 ng/mL. The intra- and inter-day precision was within 12%, with accuracies less than 7%. Stability was within the acceptable limits under various storage and processing conditions. No apparent matrix effect was detected. The validated method was applied to the pre-clinical pharmacokinetic study of DAPB after oral administration of 30 mg/kg and intravenous administration of 6 mg/kg in rats.
Collapse
Affiliation(s)
- Bei Qin
- Xi’an Key Laboratory for Research and Development of Innovative Multi-Target Antihypertensive Drugs, Xi’an Innovative Antihypertensive Drugs International Science and Technology Cooperation Base, Xi’an Medical University, Xi’an 710021, China; (Y.C.); (K.Y.); (R.W.); (L.Y.); (N.W.); (S.L.)
- Institute of Drug Research, Xi’an Medical University, Xi’an 710021, China
- College of Pharmacy, Xi’an Medical University, Xi’an 710021, China
| | - Yunmei Chen
- Xi’an Key Laboratory for Research and Development of Innovative Multi-Target Antihypertensive Drugs, Xi’an Innovative Antihypertensive Drugs International Science and Technology Cooperation Base, Xi’an Medical University, Xi’an 710021, China; (Y.C.); (K.Y.); (R.W.); (L.Y.); (N.W.); (S.L.)
- Institute of Drug Research, Xi’an Medical University, Xi’an 710021, China
- College of Pharmacy, Xi’an Medical University, Xi’an 710021, China
| | - Kuan Yang
- Xi’an Key Laboratory for Research and Development of Innovative Multi-Target Antihypertensive Drugs, Xi’an Innovative Antihypertensive Drugs International Science and Technology Cooperation Base, Xi’an Medical University, Xi’an 710021, China; (Y.C.); (K.Y.); (R.W.); (L.Y.); (N.W.); (S.L.)
- Institute of Drug Research, Xi’an Medical University, Xi’an 710021, China
- College of Pharmacy, Xi’an Medical University, Xi’an 710021, China
| | - Rong Wang
- Xi’an Key Laboratory for Research and Development of Innovative Multi-Target Antihypertensive Drugs, Xi’an Innovative Antihypertensive Drugs International Science and Technology Cooperation Base, Xi’an Medical University, Xi’an 710021, China; (Y.C.); (K.Y.); (R.W.); (L.Y.); (N.W.); (S.L.)
- Institute of Drug Research, Xi’an Medical University, Xi’an 710021, China
- College of Pharmacy, Xi’an Medical University, Xi’an 710021, China
| | - Lili Yu
- Xi’an Key Laboratory for Research and Development of Innovative Multi-Target Antihypertensive Drugs, Xi’an Innovative Antihypertensive Drugs International Science and Technology Cooperation Base, Xi’an Medical University, Xi’an 710021, China; (Y.C.); (K.Y.); (R.W.); (L.Y.); (N.W.); (S.L.)
- Institute of Drug Research, Xi’an Medical University, Xi’an 710021, China
- College of Pharmacy, Xi’an Medical University, Xi’an 710021, China
| | - Nana Wang
- Xi’an Key Laboratory for Research and Development of Innovative Multi-Target Antihypertensive Drugs, Xi’an Innovative Antihypertensive Drugs International Science and Technology Cooperation Base, Xi’an Medical University, Xi’an 710021, China; (Y.C.); (K.Y.); (R.W.); (L.Y.); (N.W.); (S.L.)
- Institute of Drug Research, Xi’an Medical University, Xi’an 710021, China
- College of Pharmacy, Xi’an Medical University, Xi’an 710021, China
| | - Shaojing Liu
- Xi’an Key Laboratory for Research and Development of Innovative Multi-Target Antihypertensive Drugs, Xi’an Innovative Antihypertensive Drugs International Science and Technology Cooperation Base, Xi’an Medical University, Xi’an 710021, China; (Y.C.); (K.Y.); (R.W.); (L.Y.); (N.W.); (S.L.)
- Institute of Drug Research, Xi’an Medical University, Xi’an 710021, China
- College of Pharmacy, Xi’an Medical University, Xi’an 710021, China
| |
Collapse
|